Trial Profile
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Radotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms RERISE
- Sponsors Il-Yang
- 04 Mar 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 03 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.